Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Brieger, KK, Peterson, S, Lee, AW, Mukherjee, B, Bakulski, KM, Alimujiang, A, Anton-Culver, H, Anglesio, MS, Bandera, EV, Berchuck, A, Bowtell, DDL, Chenevix-Trench, G, Cho, KR, Cramer, DW, DeFazio, A, Doherty, JA, Fortner, RT, Garsed, DW, Gayther, SA, Gentry-Maharaj, A, Goode, EL, Goodman, MT, Harris, HR, Høgdall, E, Huntsman, DG, Shen, H, Johnatty, SE, Jordan, SJ, Kjaer, SK, Kupryjanczyk, J, Lambrechts, D, McLean, K, Menon, U, Modugno, F, Moysich, K, Ness, R, Ramus, SJ, Richardson, J, Risch, H, Rossing, MA, Trabert, B, Wentzensen, N, Ziogas, A, Terry, KL, Wu, AH, Hanley, GE, Pharoah, P, Webb, PM, Pike, MC, Pearce, CL & Ovarian Cancer Association Consortium 2020, 'Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival', Gynecologic Oncology, bind 158, nr. 3, s. 702-709. https://doi.org/10.1016/j.ygyno.2020.06.481

APA

Brieger, K. K., Peterson, S., Lee, A. W., Mukherjee, B., Bakulski, K. M., Alimujiang, A., Anton-Culver, H., Anglesio, M. S., Bandera, E. V., Berchuck, A., Bowtell, D. D. L., Chenevix-Trench, G., Cho, K. R., Cramer, D. W., DeFazio, A., Doherty, J. A., Fortner, R. T., Garsed, D. W., Gayther, S. A., ... Ovarian Cancer Association Consortium (2020). Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 158(3), 702-709. https://doi.org/10.1016/j.ygyno.2020.06.481

CBE

Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Ovarian Cancer Association Consortium. 2020. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology. 158(3):702-709. https://doi.org/10.1016/j.ygyno.2020.06.481

MLA

Vancouver

Author

Brieger, Katharine K ; Peterson, Siri ; Lee, Alice W ; Mukherjee, Bhramar ; Bakulski, Kelly M ; Alimujiang, Aliya ; Anton-Culver, Hoda ; Anglesio, Michael S ; Bandera, Elisa V ; Berchuck, Andrew ; Bowtell, David D L ; Chenevix-Trench, Georgia ; Cho, Kathleen R ; Cramer, Daniel W ; DeFazio, Anna ; Doherty, Jennifer A ; Fortner, Renée T ; Garsed, Dale W ; Gayther, Simon A ; Gentry-Maharaj, Aleksandra ; Goode, Ellen L ; Goodman, Marc T ; Harris, Holly R ; Høgdall, Estrid ; Huntsman, David G ; Shen, Hui ; Johnatty, Sharon E ; Jordan, Susan J ; Kjaer, Susanne K ; Kupryjanczyk, Jolanta ; Lambrechts, Diether ; McLean, Karen ; Menon, Usha ; Modugno, Francesmary ; Moysich, Kirsten ; Ness, Roberta ; Ramus, Susan J ; Richardson, Jean ; Risch, Harvey ; Rossing, Mary Anne ; Trabert, Britton ; Wentzensen, Nicolas ; Ziogas, Argyrios ; Terry, Kathryn L ; Wu, Anna H ; Hanley, Gillian E ; Pharoah, Paul ; Webb, Penelope M ; Pike, Malcolm C ; Pearce, Celeste Leigh ; Ovarian Cancer Association Consortium. / Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. I: Gynecologic Oncology. 2020 ; Bind 158, Nr. 3. s. 702-709.

Bibtex

@article{85c984c478074390a1ed869d400dd0a9,
title = "Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival",
abstract = "PURPOSE: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.METHODS: Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.RESULTS: Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival.CONCLUSIONS: Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.",
author = "Brieger, {Katharine K} and Siri Peterson and Lee, {Alice W} and Bhramar Mukherjee and Bakulski, {Kelly M} and Aliya Alimujiang and Hoda Anton-Culver and Anglesio, {Michael S} and Bandera, {Elisa V} and Andrew Berchuck and Bowtell, {David D L} and Georgia Chenevix-Trench and Cho, {Kathleen R} and Cramer, {Daniel W} and Anna DeFazio and Doherty, {Jennifer A} and Fortner, {Ren{\'e}e T} and Garsed, {Dale W} and Gayther, {Simon A} and Aleksandra Gentry-Maharaj and Goode, {Ellen L} and Goodman, {Marc T} and Harris, {Holly R} and Estrid H{\o}gdall and Huntsman, {David G} and Hui Shen and Johnatty, {Sharon E} and Jordan, {Susan J} and Kjaer, {Susanne K} and Jolanta Kupryjanczyk and Diether Lambrechts and Karen McLean and Usha Menon and Francesmary Modugno and Kirsten Moysich and Roberta Ness and Ramus, {Susan J} and Jean Richardson and Harvey Risch and Rossing, {Mary Anne} and Britton Trabert and Nicolas Wentzensen and Argyrios Ziogas and Terry, {Kathryn L} and Wu, {Anna H} and Hanley, {Gillian E} and Paul Pharoah and Webb, {Penelope M} and Pike, {Malcolm C} and Pearce, {Celeste Leigh} and {Ovarian Cancer Association Consortium}",
note = "Copyright {\textcopyright} 2020 Elsevier Inc. All rights reserved.",
year = "2020",
month = sep,
doi = "10.1016/j.ygyno.2020.06.481",
language = "English",
volume = "158",
pages = "702--709",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press",
number = "3",

}

RIS

TY - JOUR

T1 - Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival

AU - Brieger, Katharine K

AU - Peterson, Siri

AU - Lee, Alice W

AU - Mukherjee, Bhramar

AU - Bakulski, Kelly M

AU - Alimujiang, Aliya

AU - Anton-Culver, Hoda

AU - Anglesio, Michael S

AU - Bandera, Elisa V

AU - Berchuck, Andrew

AU - Bowtell, David D L

AU - Chenevix-Trench, Georgia

AU - Cho, Kathleen R

AU - Cramer, Daniel W

AU - DeFazio, Anna

AU - Doherty, Jennifer A

AU - Fortner, Renée T

AU - Garsed, Dale W

AU - Gayther, Simon A

AU - Gentry-Maharaj, Aleksandra

AU - Goode, Ellen L

AU - Goodman, Marc T

AU - Harris, Holly R

AU - Høgdall, Estrid

AU - Huntsman, David G

AU - Shen, Hui

AU - Johnatty, Sharon E

AU - Jordan, Susan J

AU - Kjaer, Susanne K

AU - Kupryjanczyk, Jolanta

AU - Lambrechts, Diether

AU - McLean, Karen

AU - Menon, Usha

AU - Modugno, Francesmary

AU - Moysich, Kirsten

AU - Ness, Roberta

AU - Ramus, Susan J

AU - Richardson, Jean

AU - Risch, Harvey

AU - Rossing, Mary Anne

AU - Trabert, Britton

AU - Wentzensen, Nicolas

AU - Ziogas, Argyrios

AU - Terry, Kathryn L

AU - Wu, Anna H

AU - Hanley, Gillian E

AU - Pharoah, Paul

AU - Webb, Penelope M

AU - Pike, Malcolm C

AU - Pearce, Celeste Leigh

AU - Ovarian Cancer Association Consortium

N1 - Copyright © 2020 Elsevier Inc. All rights reserved.

PY - 2020/9

Y1 - 2020/9

N2 - PURPOSE: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.METHODS: Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.RESULTS: Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival.CONCLUSIONS: Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.

AB - PURPOSE: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.METHODS: Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.RESULTS: Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival.CONCLUSIONS: Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.

UR - http://www.scopus.com/inward/record.url?scp=85087517386&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2020.06.481

DO - 10.1016/j.ygyno.2020.06.481

M3 - Journal article

C2 - 32641237

VL - 158

SP - 702

EP - 709

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -

ID: 61556019